Telix Pharmaceuticals | TLX - 营业利润



金融业
股票价格
AUD
资产
AUD 1.16B
现金及等价物
AUD 207.16M
销售成本
AUD 221.36M
流动资产
AUD 330.28M
流动负债
AUD 231.62M
债务
AUD 418.25M
EBIT
AUD 8.04M
EBITDA
AUD 18.42M
EPS每股收益
AUD -0.05
股本和储备
AUD 416.86M
销售毛利
AUD 217.82M
债务利息支出
AUD 7.62M
利息收入
AUD 1.37M
贷款资金
AUD 448.45M
市值
AUD 5.08B
净收入
AUD -4.83M
营业费用
AUD 405.4M
营业利润
AUD 8.04M
普通股股本
AUD 338.78M
PE价格收益
244.46
税前利润
AUD 76.73M
销售收入
AUD 413.44M
销售和管理费用
AUD 93.48M
股票
AUD 35.23M
贸易债权人
AUD 71.66M
应收帐款人
AUD 135.25M


营业利润 更改 日
Cochlear AUD 261.1M 135.55M 2025-12
CSL USD 2.64B 1.97B 2025-12
Integral Diagnostics AUD 19.28M 73.95M 2024-06
Mayne Pharma AUD -3.3M 15.67M 2024-06
Medical Developments International AUD -36K 444K 2025-12
Mesoblast USD -30.96M 11.14M 2025-12
Neuren Pharmaceuticals AUD 17.01M 11.56M 2025-12
Pacific Edge NZD -16.94M 2.46M 2026-06
Paradigm Biopharmaceuticals AUD -21.57M 13.07M 2025-12
Polynovo AUD 2.06M 1.18M 2025-12
PYC Therapeutics AUD -22.59M 9.12M 2025-12
Ramsay Health Care AUD 541.1M 3.9M 2025-12
ResMed USD 500.3M 37.95M 2025-12
Sonic Healthcare AUD 435.76M 193.66M 2024-12